Probiotics and Omega-3 Fatty Acids: study protocols
10 study groups took Probiotics together with Omega-3 Fatty Acids. These are the doses the studies gave. They are not a recommendation.
Dose per serving from research: Probiotics
9 study groups in 9 studies say how much Probiotics participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 1 billion CFU to 2.5 billion CFU, 33% of 9 study groups.
| Daily dose | Study groups |
|---|---|
| 1 billion CFU to 2.5 billion CFU | 3 |
| 2.5 billion CFU to 5 billion CFU | 0 |
| 5 billion CFU to 10 billion CFU | 1 |
| 10 billion CFU to 25 billion CFU | 1 |
| 25 billion CFU to 50 billion CFU | 1 |
| 50 billion CFU to 100 billion CFU | 1 |
| 100 billion CFU to 250 billion CFU | 1 |
| 250 billion CFU to 500 billion CFU | 1 |
Dose per serving from research: Omega-3 Fatty Acids
10 study groups in 10 studies say how much Omega-3 Fatty Acids participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 1 g to 2.5 g, 30% of 10 study groups.
| Daily dose | Study groups |
|---|---|
| 100 mg to 250 mg | 2 |
| 250 mg to 500 mg | 2 |
| 500 mg to 1 g | 2 |
| 1 g to 2.5 g | 3 |
| 2.5 g to 5 g | 1 |
Commonly used together
6 of 10 study groups took Probiotics and Omega-3 Fatty Acids with something else, but nothing that 3 or more different studies gave.
10 study groups
| Study | ||||
|---|---|---|---|---|
| Effect of a Nutritional Support System to Increase Survival and Reduce Mortality in Patients with COVID-19 in Stage III and Comorbidities: A Blinded Randomized Controlled Clinical Trial 2022 · Intervention Group (IG) · Hospitalized men and women aged 30–75 years with stage III COVID-19, oxygen saturation below 90%, and comorbidities including type 2 diabetes, systemic arterial hypertension, or BMI 25–40 | 500 mg | 2 g | 3 weeks | 40 |
| Maternal fish oil and/or probiotics intervention: Allergic diseases in children up to two years old 2023 · fish oil + probiotics · Women in early pregnancy | 20 billion CFU | 220 mg | — | — |
| Strain-specific probiotic (microbial cell preparation) and omega-3 fatty acid in modulating quality of life and inflammatory markers in colorectal cancer patients: a randomized controlled trial 2018 · MCP and omega-3 fatty acid group · Colorectal cancer patients on chemotherapy | 60 billion CFU | 2 g | 8 weeks | — |
| Effectiveness of a Novel Food Composed of Leucine, Omega-3 Fatty Acids and Probiotic Lactobacillus paracasei PS23 for the Treatment of Sarcopenia in Elderly Subjects: A 2-Month Randomized Double-Blind Placebo-Controlled Trial 2022 · intervention group (OLEP) · men and women aged 55 years or older with sarcopenia | 30 billion CFU | 500 mg | 60 days | — |
| Synergistic Effects of Probiotic and Omega-3 Supplementation with Ultra-Short Race Pace Training on Sprint Swimming Performance 2025 · Probiotics + Omega-3 + USRPT (PRO + OMEGA + USRPT) · Male competitive sprint swimmers with at least five years of competitive experience and no stated disease or medical condition | 450 billion CFU | 680 mg | 8 weeks | 10 |
| Effects of maternal allergy and supplementation with ω-3 fatty acid and probiotic on human milk oligosaccharides 2025 · OL (ω-3 PUFA + L. reuteri) · Pregnant women with a family history of allergies who intended to breastfeed for the first 3 months; maternal age median about 30 years | 2 billion CFU | 3.84 g | 230 days | 36 |
| Changes in peripheral immune populations during pregnancy and modulation by probiotics and ω-3 fatty acids 2020 · ω3 + L. reuteri · Pregnant women included at gestational week 20, with at least one parent or sibling with allergic disease history or symptoms | 2 billion CFU | 1.28 g | 137 days | 22 |
| Effect of probiotic (VSL#3) and omega-3 on lipid profile, insulin sensitivity, inflammatory markers, and gut colonization in overweight adults: a randomized, controlled trial 2014 · Omega-3 capsule + VSL#3 capsule · Adults aged 40–60 of both sexes with BMI >25, apparently healthy and overweight | 113 billion CFU | 300 mg | 6 weeks | 15 |
| Synbiotic Bacillus megaterium DSM 32963 and n-3 PUFA Salt Composition Elevates Pro-Resolving Lipid Mediator Levels in Healthy Subjects: A Randomized Controlled Study 2024 · SynΩ3 group · Healthy men and women aged 30–75 years, selected as at-risk individuals with omega-3 index ≤6.5% and elevated AGEs and/or hsCRP | 2 billion CFU | 167 mg | 4 weeks | 24 |
| Potential Modulation of Inflammation by Probiotic and Omega-3 Supplementation in Elderly with Chronic Low-Grade Inflammation-A Randomized, Placebo-Controlled Trial 2022 · Active treatment group · Adults aged 65–80 with low-grade inflammation (hs-CRP 1.5–6 mg/L) and BMI 18.5–27 kg/m² | 10 billion CFU | 640 mg | 8 weeks | — |